Lapio Duo (Timolol Maleate, Latanoprost)

Timolol maleate blocks beta‑adrenergic receptors, reducing aqueous humor production, while latanoprost, a prostaglandin F2α analogue, increases uveoscleral outflow. Together they provide a synergistic reduction in intra‑ocular pressure.

The dosing regimen for Lapio Duo is determined by the prescribing ophthalmologist based on the individual patient's condition, response, and tolerance. Patients should follow the specific instructions provided by their healthcare professional.

The safety of Lapio Duo in pregnancy or lactation has not been definitively established. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and under close medical supervision.

To request Lapio Duo, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

When used as separate monotherapies, timolol reduces aqueous production and latanoprost enhances outflow. The combination in Lapio Duo offers a broader mechanism of action, often achieving greater intra‑ocular pressure reduction than either agent alone, which can be advantageous for patients needing stronger control.

Lapio Duo should be stored at room temperature, below 25 °C, in the original container. Keep the bottle tightly closed, protect it from light and moisture, and discard any solution that appears discolored or contains particles.

Lapio Duo is applied as an ophthalmic solution. The patient instills the prescribed number of drops into the affected eye(s) using the provided dropper, typically once daily in the evening, unless otherwise directed by the prescriber.

Serious risks include severe allergic reactions, significant eye pain, sudden loss of vision, corneal edema, and systemic effects such as bradycardia or hypotension, especially in patients with pre‑existing cardiovascular conditions.

Lapio Duo is contraindicated in patients with known hypersensitivity to timolol, latanoprost, or any excipients, and should be avoided in individuals with severe sinus node dysfunction, uncontrolled asthma, or acute bronchospasm without careful medical evaluation.